Core Viewpoint - The company has reported a significant decline in net profit and cash flow due to increased R&D expenses and tax payments, while also announcing a change in its drug production license to expand its production range [5][10]. Financial Performance - The net profit attributable to shareholders decreased by 32.37% year-on-year, while the net profit excluding non-recurring gains and losses fell by 70.50% [5]. - The net cash flow from operating activities dropped by 76.80% compared to the same period last year, primarily due to increased purchases and tax payments [5]. Non-Recurring Gains and Losses - The company reported a non-recurring gain of 51,027.96 yuan from personal income tax refunds and an investment income of 9,523,206.11 yuan from a merger [3][5]. License Change - The company received a new drug production license that expands its production range to include the raw material drug, Benzosulfone Melogabalin, which is intended for the production of Benzosulfone Melogabalin tablets [8][9]. - This change is expected to enhance the integration of raw material and formulation production, aiding in cost control and efficiency [10].